Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117048

A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene.

S D Markowitz, L Myeroff, M J Cooper, J Traicoff, M Kochera, J Lutterbaugh, M Swiriduk, and J K Willson

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Markowitz, S. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Myeroff, L. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Cooper, M. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Traicoff, J. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Kochera, M. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Lutterbaugh, J. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Swiriduk, M. in: PubMed | Google Scholar

Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio.

Find articles by Willson, J. in: PubMed | Google Scholar

Published March 1, 1994 - More info

Published in Volume 93, Issue 3 on March 1, 1994
J Clin Invest. 1994;93(3):1005–1013. https://doi.org/10.1172/JCI117048.
© 1994 The American Society for Clinical Investigation
Published March 1, 1994 - Version history
View PDF
Abstract

We describe the spontaneous progression of a colon adenoma cell line to tumorigenicity and growth factor independence. This system allows direct comparison of biologic stages of malignant progression with alterations of colon cancer suppressor genes and oncogenes. VACO-235, a human colon adenoma cell line, is at early passages nontumorigenic in the nude mouse, unable to grow in soft agar, growth stimulated by serum and EGF, and growth inhibited by TGF-beta. VACO-235 daughter passages 93 and higher have in culture spontaneously progressed to being weakly tumorigenic, but retain all other growth characteristics of VACO-235 early passages. A mouse xenograft from late passage VACO-235 was reestablished in culture as the granddaughter cell line, VACO-411. VACO-411 is highly tumorigenic, clones in soft agar, and is unresponsive to serum, EGF, and TGF-beta. Early passage VACO-235 bears a mutant K-ras allele, bears only mutant APC alleles, expresses no DCC transcripts, and expresses only wild type p53 transcripts. VACO-411 retains the identical genotype, still expressing only wild type p53. Colonic cells after ras mutation, APC mutation, and DCC inactivation remain nontumorigenic and growth factor dependent. Malignant progression involves at least two additional steps, and in VACO-411 can proceed by a novel pathway not requiring p53 inactivation.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1005
page 1005
icon of scanned page 1006
page 1006
icon of scanned page 1007
page 1007
icon of scanned page 1008
page 1008
icon of scanned page 1009
page 1009
icon of scanned page 1010
page 1010
icon of scanned page 1011
page 1011
icon of scanned page 1012
page 1012
icon of scanned page 1013
page 1013
Version history
  • Version 1 (March 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts